85(R) - 2017
Relating to health benefit plan coverage for ovarian cancer testing and screening.
From the LBB: no significant fiscal implication to the state is anticipated.
HB 3304 would amend the Insurance Code to require a health benefit
plan that provides coverage for diagnostic medical procedures to offer at a
minimum to each woman enrollee 18 years old and older a CA 125 blood test, a
conventional Pap smear screening, and now any other test or screening approved
by the U.S. Food and Drug Administration for the detection of ovarian cancer.
Vote Recommendation Notes
This bill violates our free market and limited government principles by mandating coverage for certain tests and screenings by private insurers. It is not a proper role of government to regulate contracts between private insurers and enrollees in the first place. In addition, a significant part of the problem of out of control healthcare and health insurance costs is a direct result of state and federal insurance mandates which drive up costs. For these reasons, we oppose HB 3304.